Is West Pharmaceutical Services Inc (WST) overvalued? · P/E 35, rev $2.89B
West Pharmaceutical Services Inc (WST) is a medical instruments & supplies company listed on US.
This page asks whether West Pharmaceutical Services Inc (WST) looks expensive on cached numbers — not a short thesis.
Latest reported WST revenue for 2024-12-31 was $2.89B. Net income was $492.7M. Revenue was down 1.9% from 2023-12-31 to 2024-12-31. WST currently screens at market cap $15.97B and trailing P/E 34.8.
WST currently screens at market cap $15.97B and trailing P/E 34.8. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next WST 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the WST stock page for the full model, not this heading.
Not investment advice.